Novel Antigen Delivery Technologies: a Review

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2015 Mar 20

PMID 25788109

Citations 1

Authors

Deepika Jain

Vikas Jain

Ranjit Singh

Affiliations

Soon will be listed here.

Abstract

Over the past few years, new insights into immunobiology and delivery systems have allowed the development of better vaccines and for a wider range of diseases. Currently available vaccines represent outstanding success story in modern medicine and have had a dramatic effect on morbidity and mortality worldwide. Conventional vaccines have been based on live attenuated, or killed, viruses or bacteria, or recombinant proteins from these organisms. The design of live attenuated vaccines depended to some extent on serendipity and resulted in low success rates. Both live attenuated and killed vaccines require handling of live pathogens and are associated with safety problems. Despite the success of vaccines, there is a clear need for novel antigen delivery technologies to improve vaccine efficacy and safety. Antigen stability, safety, and immunogenicity are the key hurdles in development of novel antigen delivery technologies. Nowadays, various novel drug delivery systems are becoming one of the fastest growing sectors in the pharmaceutical and biotechnological industries. Delivery of vaccines via oral, intranasal, transcutaneous, and intradermal routes will decrease the risk of needle-borne diseases and may eliminate the need for trained personnel and sterile equipment. Currently, various techniques involving DNA vaccines, adjuvants, nanoparticles, liposome, microneedle, and NanoMAP technology are being developed and evaluated. This review focuses on the current development of some novel vaccine delivery systems and will explore the non-parenteral routes of vaccine administrations.

Citing Articles

Attitudes and acceptance of vaccination against neglected tropical diseases: A multi-country study in Asia.

Wong L, Lee H, Alias H, Seheli F, Lachyan A, Nguyen D Hum Vaccin Immunother. 2025; 21(1):2471702.

PMID: 40050267 PMC: 11901362. DOI: 10.1080/21645515.2025.2471702.

Immune cell engineering: opportunities in lung cancer therapeutics.

Bhargava A, Mishra D, Tiwari R, Lohiya N, Goryacheva I, Mishra P Drug Deliv Transl Res. 2020; 10(5):1203-1227.

PMID: 32172351 DOI: 10.1007/s13346-020-00719-2.

References

Liu M . Vaccine developments. Nat Med. 1998; 4(5 Suppl):515-9. DOI: 10.1038/nm0598supp-515. View

Esquisabel A, Hernandez R, Igartua M, Gascon A, Calvo B, Pedraz J . Effect of lecithins on BCG-alginate-PLL microcapsule particle size and stability upon storage. J Microencapsul. 2000; 17(3):363-72. DOI: 10.1080/026520400288328. View

Eldridge J, Staas J, Meulbroek J, Tice T, Gilley R . Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991; 59(9):2978-86. PMC: 258122. DOI: 10.1128/iai.59.9.2978-2986.1991. View

Commander N, Brewer J, Wren B, Spencer S, Macmillan A, Stack J . Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge. Genet Vaccines Ther. 2010; 8:5. PMC: 2918601. DOI: 10.1186/1479-0556-8-5. View

Bal S, Ding Z, Kersten G, Jiskoot W, Bouwstra J . Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm Res. 2010; 27(9):1837-47. PMC: 2920068. DOI: 10.1007/s11095-010-0182-y. View

Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J . Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog. 2010; 6(11):e1001147. PMC: 2978714. DOI: 10.1371/journal.ppat.1001147. View

Scharton-Kersten T, Glenn G, Vassell R, Yu J, Walwender D, Alving C . Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine. 1999; 17 Suppl 2:S37-43. DOI: 10.1016/s0264-410x(99)00233-9. View

Reis E, Jacobson R, Tarbell S, Weniger B . Taking the sting out of shots: control of vaccination-associated pain and adverse reactions. Pediatr Ann. 1998; 27(6):375-86. DOI: 10.3928/0090-4481-19980601-12. View

Chan L, Lee H, Heng P . Production of alginate microspheres by internal gelation using an emulsification method. Int J Pharm. 2002; 242(1-2):259-62. DOI: 10.1016/s0378-5173(02)00170-9. View

10.

Bowersock T, HogenEsch H, Suckow M, Guimond P, Martin S, Borie D . Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine. 1999; 17(13-14):1804-11. DOI: 10.1016/s0264-410x(98)00437-x. View

11.

Glenn G, Scharton-Kersten T, Vassell R, Mallett C, Hale T, Alving C . Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol. 1998; 161(7):3211-4. View

12.

Tabata Y, Ikada Y . Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials. 1988; 9(4):356-62. DOI: 10.1016/0142-9612(88)90033-6. View

13.

Borges O, Lebre F, Bento D, Borchard G, Junginger H . Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res. 2009; 27(2):211-23. DOI: 10.1007/s11095-009-0011-3. View

14.

Hathaway L, Kraehenbuhl J . The role of M cells in mucosal immunity. Cell Mol Life Sci. 2000; 57(2):323-32. PMC: 11146756. DOI: 10.1007/PL00000693. View

15.

Coppi G, Iannuccelli V, Leo E, BERNABEI M, CAMERONI R . Protein immobilization in crosslinked alginate microparticles. J Microencapsul. 2002; 19(1):37-44. DOI: 10.1080/02652040110055621. View

16.

Kulkarni A, Soppimath K, Aminabhavi T, Rudzinski W . In-vitro release kinetics of cefadroxil-loaded sodium alginate interpenetrating network beads. Eur J Pharm Biopharm. 2001; 51(2):127-33. DOI: 10.1016/s0939-6411(00)00150-8. View

17.

Florence A . The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997; 14(3):259-66. DOI: 10.1023/a:1012029517394. View

18.

Karkada M, Weir G, Quinton T, Fuentes-Ortega A, Mansour M . A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine. 2010; 28(38):6176-82. DOI: 10.1016/j.vaccine.2010.07.025. View

19.

Li X, Kong X, Shi S, Zheng X, Guo G, Wei Y . Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol. 2008; 8:89. PMC: 2603011. DOI: 10.1186/1472-6750-8-89. View

20.

Gonzalez Ferreiro M, Tillman L, Hardee G, Bodmeier R . Characterization of alginate/poly-L-lysine particles as antisense oligonucleotide carriers. Int J Pharm. 2002; 239(1-2):47-59. DOI: 10.1016/s0378-5173(02)00030-3. View